B-Cell Depletion in Autoimmune Disease-Considerations for Early Clinical Development Summary

Key insights include: 

• Early-phase strategy for healthy volunteers versus patients 
• Clinical development considerations for in vivo CAR-T and T-cell engagers 
• Basket study design and adaptive protocol planning in autoimmune disease 
• Safety, biomarker logistics, and B-cell depletion kinetics in early studies 
• Australia’s role in early-phase autoimmune clinical development

Download whitepaper on B-cell depletion strategies, early-phase trial design, and autoimmune clinical development insights.

B-cell-targeted therapies are reshaping the development landscape in autoimmune disease. Insights from oncology are now helping to define a clearer development path for deep B-cell depletion approaches in severe, treatment-resistant autoimmune conditions. Newer modalities, including in vivo CAR-T and T-cell engagers, are expanding the field beyond conventional suppression toward strategies that achieve deeper depletion, with the potential for longer remissions and reduced treatment burden.

For sponsors, the challenge is not only scientific. It increasingly involves designing early-phase studies that generate meaningful safety, pharmacodynamic, and efficacy data. One of the key decisions is whether to begin in healthy volunteers or patients. Healthy volunteer studies can help clarify dose–depletion and recovery kinetics, while patient studies can provide earlier disease-relevant pharmacodynamic and efficacy signals. Basket designs, adaptive pivots from healthy volunteers to patients, and rapid biomarker turnaround are all becoming important parts of early-phase strategy.

This whitepaper examines the clinical development considerations that shape B-cell-targeted therapies for autoimmune disease. It explores the development of in vivo CAR-T and T-cell engagers, the choice between healthy volunteers and patients, important safety considerations including cytokine release syndrome and Australia’s role in early-phase clinical development.